MolecuLight to Showcase Innovative Wound Imaging Platform at the Society for Vascular Surgery Vascular Annual Meeting 2025

MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

For sales, media or other inquiries or further information, please contact: Danielle Dunham, Director of Product, MolecuLight Inc., T. +1.416.542.5524, [e-mail], www.MolecuLight.com

Photo - https://mma.prnewswire.com/media/2696279/MolecuLight_MolecuLight_to_Showcase_Innovative_Wound_Imaging_Pla.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-to-showcase-innovative-wound-imaging-platform-at-the-society-for-vascular-surgery-vascular-annual-meeting-vam-2025-302465625.html